The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer
The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
TOPARP-B was a randomised, phase 2 study that compared 300 mg versus 400 mg twice daily oral olaparib through a pick-the-winner design. 711 patients previously treated with chemotherapy consented to prescreening, of whom 592 underwent targeted next-generation sequencing for DDR aberrations. [...]119 (17%) patients in TOPARP-B could not be molecular...
Alternative Titles
Full title
The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2322740678
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2322740678
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(19)30780-6
